Is bcrx a good stock to buy? Jefferies financial group lowered biocryst pharmaceuticals from a buy rating to a hold rating and set a $19.00 price target on the stock.
None of the analysts recommend a sell.
Is bcrx a buy. The highest sales estimate is $50.88 million and the lowest is $ At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. (nasdaq:bcrx), which was worth $94.6 million at the end of the.
Et on tipranks.com analysts estimate biocryst pharmaceuticals (bcrx) to report a decline in earnings: In the meantime, 0 analyst(s) believe the stock as underweight and 0 think it is a sell. The company had a trading volume of 3,400,194 shares, compared to its average volume of 4,346,498.
Today, the average trading volume of bcrx was 3.51m shares. Amgen bought the drug otezla for ~13. Is bcrx a good stock to buy now?
Four analysts have provided estimates for biocryst pharmaceuticals' earnings. Bcrx currently public float of 176.16m and currently shorts hold a 10.43% ratio of that float. The number of long hedge fund positions were trimmed by 4 lately.
Jmp securities reaffirmed a buy rating and set a $23.00 target price on shares of biocryst pharmaceuticals in a report on thursday, september 16th. (nasdaq:bcrx) will announce sales of $46.56 million for the current quarter, zacks reports. And the buy came after the announcement of the $350 million cash infusion.
The best stock pickers were taking a pessimistic view. The stock is rated as a hold by 3 analyst(s), 9 recommend it as a buy and 0 called the bcrx stock overweight. Ma, sg americas securities llc, and citadel advisors llc.
(nasdaq:bcrx) senior vp & cfo just bought 60% more shares investors who take an interest in biocryst pharmaceuticals, inc. 28, 2021 at 12:25 p.m. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is overweight.
One research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. An investment in bcrx stock comes with risk, just like any other investment you’ll ever make. (nasdaq:bcrx) have received an average recommendation of buy from the thirteen ratings firms that are covering the firm, marketbeat reports.
(nasdaq:bcrx) has a beta value of 2.42 and has seen 2.68 million shares traded in the last trading session. Jmp securities keeps a buy rating on biocryst (bcrx) oct. Bcrx stock was purchased by a variety of institutional investors in the last quarter, including two sigma advisers lp, fisher asset management llc, bioimpact capital llc, voloridge investment management llc, two sigma investments lp, granahan investment management inc.
Based on estimates by 12 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 3 have rated the biocryst pharmaceuticals inc. In a research report on friday, august 6th. Should i buy biocryst pharmaceuticals (bcrx)?
Wall street analysts forecast that biocryst pharmaceuticals, inc. 1 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a sell. This rating represents a strong buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents sell, 3 is hold, and 2 indicates buy.
Among these funds, baker bros. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current wall street consensus on bcrx stock is a recommendation set at 2.20. According to data from marketbeat, biocryst pharmaceuticals has an average rating of buy and an average target price of $20.20.
Advisors held the most valuable stake in biocryst pharmaceuticals, inc. Among the 11 analysts tracking bcrx, eight recommend a buy and three recommend a hold. Royal bank of canada reduced their target price on biocryst pharmaceuticals from $16.00 to $14.00 and set a sector perform rating for the company in a report on thursday, november 4th.
Biocryst pharmaceuticals holds several positive signals, but we still don't find these to be enough for a buy candidate. A number of equities research analysts have issued reports on bcrx shares. (bcrx) stock as a hold, while 8 rate it as a buy.
Their highest target price of $20 is 28 percent above the stock's. Risks to consider before buying bcrx stock. Biocryst pharmaceuticals (bcrx) q2 2021 earnings call transcript;
Shares of biocryst pharmaceuticals, inc. The $400,000+ open market purchase of stock by the cfo is the vote of confidence that every biotech hopes for. Use the zacks rank and style scores to find out is bcrx is right for your portfolio.
Why biocryst pharmaceuticals rose 8% on thursday There is a buy signal from a pivot bottom found 1 days ago.) is biocryst pharmaceuticals stock a buy? (nasdaq:bcrx) senior vp & cfo just bought 60% more shares investors who take an interest in biocryst pharmaceuticals, inc.
